Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
BMC Cardiovasc Disord. 2022 May 10;22(1):212. doi: 10.1186/s12872-022-02637-2.
Patients with type 2 diabetes mellitus (T2DM) are prone to develop non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD). We aimed to investigate whether the resveratrol supplementation improves novel hepatic and cardiovascular indices in these patients.
We conducted a double-blind, randomized controlled trial for 8 weeks. Seventy-six patients with T2DM were randomly assigned to receive 1000 mg/day resveratrol or placebo. Levels of lipid accumulation product (LAP), visceral adiposity index (VAI), Castelli risk index I (CRI-I), CRI-II and atherogenic coefficient (AC) were measured at the beginning and after intervention.
A total of 71 participants completed the trial. After adjusting for confounding factors including medications, diabetes duration, energy intake and physical activity, no significant difference was found between the intervention group and the control group in LAP (mean change: - 2.46 ± 23.3 vs. 1.43 ± 14.3; P = 0.43), VAI (mean change: - 0.25 ± 1.1 vs. - 0.02 ± 0.6; P = 0.47), CRI-I (mean change: - 0.25 ± 0.9 vs. - 0.09 ± 0.5; P = 0.79), CRI-II (mean change: - 0.23 ± 0.7 vs. - 0.06 ± 0.6; P = 0.38) and AC (mean change: - 0.25 ± 0.9 vs. - 0.09 ± 0.5; P = 0.79).
Resveratrol supplementation had no effect on hepatic steatosis and cardiovascular indices. Further clinical trials, especially among subjects with dyslipidemia are needed to reach a firm conclusion. In addition, taking all medications should be controlled in future studies. Trial registration The protocol was registered on 29/12/2017 at the Iranian clinical trials website (IRCT20171118037528N1) with URL: https://en.irct.ir/trial/27734 .
2 型糖尿病（T2DM）患者易发生非酒精性脂肪性肝病（NAFLD）和心血管疾病（CVD）。本研究旨在探讨白藜芦醇补充剂是否能改善这些患者的新型肝脏和心血管指标。
我们进行了为期 8 周的双盲、随机对照试验。76 例 T2DM 患者被随机分为接受 1000mg/天白藜芦醇或安慰剂。在干预前后测量脂质蓄积产物（LAP）、内脏脂肪指数（VAI）、卡斯特利风险指数 I（CRI-I）、CRI-II 和致动脉粥样硬化系数（AC）的水平。
共有 71 名参与者完成了试验。在调整了药物、糖尿病病程、能量摄入和体力活动等混杂因素后，干预组和对照组之间 LAP（平均变化：-2.46±23.3 与 1.43±14.3；P=0.43）、VAI（平均变化：-0.25±1.1 与-0.02±0.6；P=0.47）、CRI-I（平均变化：-0.25±0.9 与-0.09±0.5；P=0.79）、CRI-II（平均变化：-0.23±0.7 与-0.06±0.6；P=0.38）和 AC（平均变化：-0.25±0.9 与-0.09±0.5；P=0.79）均无显著差异。
白藜芦醇补充剂对肝脂肪变性和心血管指标没有影响。需要进一步的临床试验，特别是在血脂异常的患者中，以得出更确定的结论。此外，未来的研究应控制所有药物的使用。
该方案于 2017 年 12 月 29 日在伊朗临床试验网站（IRCT20171118037528N1）注册，网址为：https://en.irct.ir/trial/27734。
